CVS Caremark will place Eli Lilly’s Zepbound on commercial formularies as an additional preferred option starting Oct. 1, reopening a coverage path for employer plans that dropped GLP-1 weight-loss benefits during 2025’s cost crunch. Lilly’s public supply tracker lists every Zepbound pen and vial dose as available nationwide, though the company warns that individual pharmacies may still fill prescriptions slowly—a split screen that matters for workers trying to use insurance before year-end benefit resets.
Coverage is not automatic
Lilly said in May that Caremark would resume Zepbound on template plans by October while continuing Foundayo coverage that began in June. Plan sponsors must still opt into obesity pharmacotherapy; CVS announcements emphasize that employers retain discretion to exclude weight-loss drugs even when the PBM lists them as preferred. Surveys cited by benefits consultants this summer found a double-digit share of large employers dropping or planning to drop GLP-1 coverage by 2027, meaning Oct. 1 is a door—not a guarantee—for every cardholder.
Workers should pull their 2027 summary of benefits and confirm whether tirzepatide is on the formulary with prior authorization, step therapy, or body-mass-index requirements. Human resources offices often finalize open-enrollment packets in October, making this week the last chance to flag medical-necessity documentation before deductibles reset Jan. 1.
Supply versus access
Lilly’s supply site distinguishes “available” pen strengths from vial formats that may face location-specific delays. That nuance matters because vials can be cheaper for cash-paying patients when savings cards cap pen copays. The company’s Employer Connect program, launched in March, routes KwikPens through independent administrators at a $449 list price to pharmacies before employer subsidies and employee cost-sharing.
Patients with commercial coverage may still use Lilly’s savings card to reach $25 copays on pens while the card remains valid through Dec. 31, 2026, according to published terms; government program enrollees are excluded and must look to Medicare’s GLP-1 Bridge pricing where eligible.
Clinical and cost guardrails
Zepbound is FDA-approved for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity—not cosmetic weight loss. Lilly has publicly opposed off-label cosmetic demand that strained earlier shortages. Employers adopting Oct. 1 coverage often pair it with lifestyle programs administered by vendors such as Teladoc or Calibrate, listed as Lilly partners.
The reader action is verification: call the PBM benefits line, confirm the NDC for the prescribed strength, and ask whether mail-order pharmacies in the network actually have stock. Coverage without inventory repeats the 2024 frustration; inventory without coverage pushes patients toward $499-a-month cash pen offers. October is the month those two variables align—or do not—for millions of commercially insured adults.